Open, randomized trial of the effect of aripiprazole versus risperidone on social cognition in schizophrenia.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON26432

Enrollment

Registered

2005-10-27

Start date

2005-12-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

80 schizophrenia patients are randomly assigned to either risperidone (4 mg) or aripiprazole (15 mg). Performance on social cognitive tasks are measured at baseline level and after 8 weeks of treatment.

Interventions

80 schizophrenia patients are randomly assigned to either risperidone (4 mg) or aripiprazole (15 mg).

Eligibility

Inclusion criteria

Inclusion criteria: 1. DSM-IV based diagnosis of schizophrenia; 2. Age 18 - 50; 3. Active anticonception; 4. IQ > 80; 5. Negative pregnancy test.

Exclusion criteria

Exclusion criteria: 1. Pregnancy; 2. Lactation; 3. Severe head trauma; 4. Substance abuse.

Design outcomes

Primary

Measure	Time frame
The effect of treatment with risperidone or aripiprazole on social cognitive processes in patients with schizophrenia is the primary result of this study. These processes are assessed using computerised cognitive tasks. The objective of the study is to determine which of the two antipsychotics is the most effective against social cognitive deficits.	—

Contacts

Public ContactThomas Rietkerk

University Medical Center Utrecht (UMCU), B.01.206, P.O. Box 85500

T.Rietkerk@azu.nl+31 (0)30 2506369

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)